Jichuan Pharmaceutical (600566.SH): The company's products have been preliminarily selected for the centralized volume-based procurement of the National Traditional Chinese Medicine Procurement Alliance.

Gelonghui reported on May 7 that Ji Chuan Pharmaceutical (600566.SH) announced its wholly-owned subsidiary, Ji Chuan Pharmaceutical Group Co., Ltd., participated in the centralized volume-based procurement work of the National Traditional Chinese Medicine Procurement Alliance. According to the announcement titled 'Display of Tentative Winning Results for Centralized Volume-Based Procurement of the National Traditional Chinese Medicine Procurement Alliance' released by the Hubei Medical Insurance Service Platform on April 30, 2026, Ji Chuan's product Jianwei Xiaoshi Oral Liquid is tentatively selected for this centralized volume-based procurement. The revenue from the above-mentioned tentatively selected product Jianwei Xiaoshi Oral Liquid in the fiscal year 2025 was RMB 453.5225 million, accounting for 7% of the company’s total operating income in 2025.

Gelonghui FinanceMay 7 16:57

Jichuan Pharmaceutical (600566.SH): Cumulative repurchase of 934,700 company shares

Gelonghui, May 7th - Jichuan Pharmaceutical (600566.SH) announced that as of April 30, 2026, the company has cumulatively repurchased 934,700 shares through centralized bidding, accounting for 0.10% of the company’s total share capital. The highest purchase price was RMB 27.49 per share, and the lowest was RMB 25.94 per share. The total amount paid was RMB 25,000,953 (excluding transaction fees).

Gelonghui FinanceMay 7 16:56

Jichuan Pharmaceutical (600566) 2025 Annual Report Commentary: Short-term Performance Under Pressure, Focus on the Development of New Products

Report Summary: The company's short-term performance is under pressure due to fluctuations in end-user demand and the impact of centralized procurement. However, the company maintains a high dividend payout ratio and expands its pipeline through independent innovation and external collaboration, with a focus on long-term value. Key Investment Points: Maintain 'Overweight' rating. Adjustments.

Guotai Haitong SecuritiesMay 1 00:00

Jichuan Pharmaceutical (600566): Maintaining High Cash Dividend Payout Ratio, Innovation R&D and Collaborative Partnerships Driving Medium- to Long-Term Growth

Event: The company released its 2025 annual report, with Q4 performance showing improvement. In 2025, the company achieved operating revenue of 6.219 billion yuan, representing a year-on-year decrease of 22.43%; net profit attributable to shareholders was 1.778 billion yuan, down 2% year-on-year.

SDIC SecuritiesApr 29 20:51

Jichuan Pharmaceutical (600566): Performance under pressure in 2025, BD collaboration to empower future development

The company is under pressure in terms of performance for the current phase. However, its growth potential driven by R&D and business development (BD) layout is highly anticipated. The 'Buy' rating is maintained. The company is projected to achieve revenue of 6.219 billion yuan in 2025 (a year-on-year decrease of 22.43%; all subsequent figures are on a year-on-year basis); net profit attributable to shareholders is expected to be...

Open Source SecuritiesApr 29 07:47

Jichuan Pharmaceutical (600566): Strong Q4 performance in 2025, supported by high dividend and BD catalysts.

The financial performance in Q4 2025 was impressive, primarily due to an unexpected surge in the number of influenza cases during the same period. In 2025, the company generated revenue of 6.219 billion yuan (a year-on-year decrease of 22.43%) and reported a net profit attributable to shareholders of 1.7 billion yuan.

Great Wall SecuritiesApr 28 12:37